Cervical Cancer News and Research RSS Feed - Cervical Cancer News and Research

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.
Moffitt researchers find cancer healthcare disparities in LGBTQ community

Moffitt researchers find cancer healthcare disparities in LGBTQ community

The Lesbian, Gay, Bisexual, Transgender/Transsexual, Queer/Questioning (LGBTQ) community is a growing and medically-underserved minority population in the United States, with 3 to 12 percent of the population estimated to identify as LGBTQ. [More]
Cincinnati Children's doctors remind parents about the importance of immunizing kids before sending them to school

Cincinnati Children's doctors remind parents about the importance of immunizing kids before sending them to school

Doctors at Cincinnati Children's Hospital Medical Center want to remind parents about the importance of immunizing their children when preparing to send their children back to school. [More]
Study reveals impact of patient navigator program on no-show rates for cervical cancer screening

Study reveals impact of patient navigator program on no-show rates for cervical cancer screening

Researchers at Harvard Medical School and Brigham and Women's Hospital reported a 20% decline in the rate of missed appointments for cervical cancer evaluation following a Pap smear when a patient navigator program was initiated at the referral center. [More]
Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig Cancer Research and the Cancer Research Institute have launched clinical trials evaluating an immunotherapy for the treatment of the brain cancer glioblastoma multiforme (GBM), and a combination of immunotherapies for a variety of solid tumors. [More]

DSMB recommends continuation of Genticel’s GTL001 phase 2 trial in HPV-infected women

Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the independent Data Safety Monitoring Board recommends the continuation, per protocol, of its phase 2 clinical trial of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases. [More]
Study: Extended-field IMRT for cervical or endometrial cancer does not increase risk of duodenal toxicity

Study: Extended-field IMRT for cervical or endometrial cancer does not increase risk of duodenal toxicity

A study of women with cervical or endometrial cancer who require treatment to the para-aortic (PA) lymph nodes can safely receive extended-field intensity modulated radiation therapy (EF-IMRT) without increased risk of duodenal toxicity, according to a study published in the July-August 2015 issue of Practical Radiation Oncology, the American Society for Radiation Oncology's journal focused on the clinical practice of radiation oncology. [More]
New public guide addresses unrealistic expectations of screening tests

New public guide addresses unrealistic expectations of screening tests

Misconceptions about how screening works, its limitations and possible harms are still being perpetuated by media stories and high profile cases, such as Angelina Jolie's double mastectomy and emotive tabloid case studies of women under 25 dying from cervical cancer. [More]
CPhA urges federal government to enhance HPV vaccination programs for young Canadians

CPhA urges federal government to enhance HPV vaccination programs for young Canadians

The Canadian Pharmacists Association (CPhA) urges the federal government to enhance its national immunization strategy to ensure that all Canadians have the opportunity to protect themselves against the common strains of HPV (human papillomavirus) through immunization. [More]
Findings reveal new pathway to develop effective treatments and therapies for asthma, allergy

Findings reveal new pathway to develop effective treatments and therapies for asthma, allergy

Investigators have discovered the precise molecular steps that enable immune cells implicated in certain forms of asthma and allergy to develop and survive in the body. The findings from Weill Cornell Medical College reveal a new pathway that scientists could use to develop more effective treatments and therapies for the chronic lung disorder. [More]
Roswell Park, Lakeshore Cancer Center partner to improve access to cancer care for Nigerians

Roswell Park, Lakeshore Cancer Center partner to improve access to cancer care for Nigerians

America's oldest cancer center and one of the world's newest oncology centers are partnering to improve access to cancer prevention, screening and care for the people of Nigeria. Roswell Park Cancer Institute and Lakeshore Cancer Center have announced an affiliation that will see Roswell Park faculty providing clinical consultations to assist LCC oncologists, who will also have access to both training at RPCI and continuing professional education seminars they can participate in remotely. [More]
BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other territories. [More]
Study suggests link between fatalistic beliefs and completion of HPV vaccine series among Appalachian women

Study suggests link between fatalistic beliefs and completion of HPV vaccine series among Appalachian women

Could a fatalistic attitude toward cervical cancer serve as a barrier to prevention of the disease? A recent study conducted by University of Kentucky researchers in the Rural Cancer Prevention Center suggests a link between fatalistic beliefs and completion of the human papillomavirus (HPV) vaccine series among a sample of young Appalachian Kentucky women. [More]
The Mary Kay Foundation awards $1.3 million grant to advance cancer research and discovery

The Mary Kay Foundation awards $1.3 million grant to advance cancer research and discovery

With more than 800,000 new cases of cancer among women in the United States expected this year, according to the American Cancer Society, almost everyone is touched by the disease. [More]
WHO prequalifies new male circumcision device to prevent HIV

WHO prequalifies new male circumcision device to prevent HIV

The ShangRing, a novel medical device for voluntary medical male circumcision, has received prequalification from the World Health Organization (WHO) for use. [More]

Rates of high-grade cervical lesions decrease in young U.S. women following availability of HPV vaccines

A new analysis indicates that rates of high-grade cervical lesions decreased in young U.S. women after vaccines were made available to protect against human papillomavirus (HPV), but the trend may be due in part to changes in cervical cancer screening recommendations. [More]
PD linked to increased cancer risk in Asian population

PD linked to increased cancer risk in Asian population

A Taiwanese population-based cohort study reports an increased risk of most cancers in patients with Parkinson’s disease, contrasting with findings in Western populations. [More]
Bivalent HPV vaccine efficacy may be independent of dose

Bivalent HPV vaccine efficacy may be independent of dose

Fewer than three doses of the bivalent human papillomavirus vaccine may be sufficient to offer adequate protection against cervical HPV-16 and -18 infection, research published in The Lancet Oncology indicates. [More]
Nanoplatform technology that detects early stages of cancer receives U.S. patent

Nanoplatform technology that detects early stages of cancer receives U.S. patent

A U.S. patent has been awarded to a Kansas State University technology that quickly detects the early stages of cancer before physical symptoms ever appear. [More]
CINtec PLUS Cytology test more effective than HC2 HPV test in identifying women with precancerous lesions

CINtec PLUS Cytology test more effective than HC2 HPV test in identifying women with precancerous lesions

Ventana Medical Systems, Inc., a member of the Roche Group, today announced the publication of further results from the Primary ASC-US LSIL Marker Study (PALMS) in this month's issue of Cancer Cytopathology. The PALMS study, which enrolled more than 27,000 women from five European countries, was designed to evaluate the diagnostic performance of the CINtec PLUS Cytology test in detecting pre-cancerous cervical disease compared to HPV testing and more traditional screening methods like Pap cytology. [More]
Genticel’s GTL001 phase 1 clinical study of HPV therapeutic vaccine granted FDA clearance

Genticel’s GTL001 phase 1 clinical study of HPV therapeutic vaccine granted FDA clearance

Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel’s Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases. [More]
Advertisement